Navigation Links
CV Therapeutics Reports 2008 First Quarter Financial Results
Date:4/25/2008

reement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on From 10-K for the year ended December 31, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

CV THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Amounts)

(Unaudited)

Three months ended

March 31,

2008 2007

Revenues:

Product sales, net $22,045 $11,989

Collaborative research 766 3,261

Total revenues 22,811 15,250

Costs and expenses:

Cost of sales 3,383 1,557

Research and development 17,245 27,178

Selling, general and administrative 32,450 42,448

Restructuring charges (7) -

Total costs and expenses 53,071 71,183

Loss from operations (30,260) (55,933)

Other income (expense), net:

Interest and other income, net 1,535 4,043

Interest expense (3,174) (3,166)

Total other income (expense), net
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... , Dec. 11, 2014 Research and Markets ... addition of the "Glucose Sensors: the Next ... http://photos.prnewswire.com/prnh/20130307/600769 The ... designs is giving hope for a better future ... monitors that can measure glucose levels accurately and ...
(Date:12/13/2014)... and SAN ANTONIO , Dec. 12, ... announced the presentation of data at the San Antonio ... study evaluating epoetin alfa plus best supportive care (BSC) ... with metastatic breast cancer receiving standard chemotherapy. This non-inferiority ... to rule out a 15 percent or greater increase ...
(Date:12/12/2014)... Graphite Metallizing Corporation, the manufacturer of ... process equipment, has appointed Kirk Staller as Sales Engineering ... Staller holds a B.S. degree from Purdue University and ... place, much of it with a manufacturer of centrifugal ... office. , “We are pleased to have ...
(Date:12/12/2014)... 2014 Electronic Data Interchange (EDI) ... management and supply chain management to depend from ... The benefits associated with the use of EDI ... transactions has helped improve the acceptance of this ... market data tables and 107 figures spread through ...
Breaking Biology Technology:Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4
... Ill., July 29 The Board of,Directors of Baxter ... dividend of $0.2175 per share of Baxter common stock., ... rate, which was,increased earlier this year by 30 percent. ... shareholders of record as of September 10,2008., Baxter ...
... an Antipsychotic Agent with Less Potential for ... Gain and Metabolic Risks, SAN DIEGO, July 29 ... that the United States Patent and,Trademark Office (USPTO) issued ... provide broad coverage for a pharmaceutical,composition of zonisamide in ...
... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced ... in a,single-center, Phase 1 trial of recombinant, ... its Wnt Therapeutics Program. This,double-blind, placebo-controlled, single-ascending ... and pharmacokinetics of a single,intravenous (IV) administration ...
Cached Biology Technology:OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... toxins or nefarious germs, smaller and faster is better. ... especially when measurements by different instruments must give the ... standarda culmination of years of research at the National ... from handheld chemical detectors can be compared, apples-to-apples. ...
... of the most species-rich ant genera, latest research has stripped ... species- Paratrechina longicornis . This particular ant is one ... tropical and subtropical location on the planet due to accidental ... invasive ant species. A recent review of the genus in ...
... news release is available in German . ... on a course of treatment, tests can be carried out ... is likely to be effective. But the time-consuming and expensive ... Collaborating with DITABIS Digital Biomedical Imaging Systems AG and scientists ...
Cached Biology News:New spectrometry standard for handheld chemical detectors aids first responders 2The most widespread ant and its new relative: A revision of the genus Paratrechina 2A cost-effective way toward personalized cancer drugs 2A cost-effective way toward personalized cancer drugs 3